Hot Stocks Formula Review in Health Sector (PFE, BSX, ARNA, MRK)

New York, NY -- (SBWIRE) -- 10/19/2012 -- Pfizer (NYSE: PFE)‘s stock had its “outperform” rating restated by equities researchers at BMO Capital Markets in a report issued on Thursday. They currently have a $30.00 target price on the stock.Pfizer traded up 0.65% on Thursday, hitting $26.0069. Pfizer has a 52-week low of $18.15 and a 52-week high of $25.93. The company has a market cap of $194.3 billion and a price-to-earnings ratio of 19.37.Pfizer last posted its quarterly earnings results on Tuesday, July 31st. The company reported $0.62 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.54 by $0.08. The company’s quarterly revenue was down 8.7% on a year-over-year basis.

Can PFE Continue To Move Higher? Find Out Here

Boston Scientific Corporation (NYSE:BSX) For the third quarter ended September 30, 2012, Boston Scientific Corporation (NYSE:BSX) announced sales were US$1.735 billion, down 7% from sales of US$1.874 billion for the third quarter of 2011. On a GAAP basis, net loss was US$725 million (or a loss of US$0.52 per share) for the latest quarter, compared with net income of 142 million (or US$0.09 per share) in the prior-year quarter. Following the announcement, shares of Boston Scientific crossed below the 50-day moving average and tumbled US$0.22 (or -3.91%) to close at US$5.40. Boston Scientific has a market capitalization of US$7.66 billion with price range within US$4.79 - US$6.41 over the past 52 weeks. There were 31.55 million stock shares traded, which was 3 times more than average volume.

How Should Investors Trade BSX Now? Sign Up To Know

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declined sharply, trimming gains after the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811. The company has a market value of $2.07 billion.It employs 266 people, over the last 12 months has generated revenue of $29.70 million and has a net income of -$97.92 million. The firm’s operating margin is -207.78 percent and net profit margin -320.17 percent. The latest closing price of its shares moved up 10.95% from the 50-day moving average.

Should Investor Buy / Sell Or Hold This Stock : CLICK HERE

Merck & Co. (NYSE:MRK): The medical product Isentress received a positive opinion from the Committee for Medicinal Products for Human Use, or CHMP, which recommends a variation to its terms of the marketing authorization for the product. Merck Sharp & Dohme holds the marketing authorization holder for Isentress, and may request a reexamination of the CHMP opinion, assuming that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion. The extension adopted by the Committee is to add two new strengths and a new pharmaceutical form, 25 mg and 100 mg chewable tablets, to the existing array of products. Further, the Committee adopted the following changes to an indication: “Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus infection in adults, adolescents, and children from the age of 2 years.” Shares of Merck & Company, (NYSE: MRK) are trading at $47.22 and is +4.75% of its 50-day Moving Average price of $45.0769 and +13.46% from its 200-day Moving Average price of $41.6198. The average trading volume is 11258600 shares and its market capitalization is $143.8B.

Will MRK Stable This Position Or Not? FREE MRK Technical Analysis, Please Visit Here

DISCLAIMER:

Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz